A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease

Trial Profile

A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 22 Mar 2016 Planned number of patients changed to 149 as reported by ClinicalTrials.gov.
    • 22 Mar 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 04 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top